Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals Incorporated    VRTX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/13/2017 02/14/2017 02/15/2017 02/16/2017 02/17/2017 Date
87.72(c) 88.91(c) 89.37(c) 87.7(c) 88.33(c) Last
1 123 459 2 321 559 1 329 771 1 322 193 1 425 087 Volume
-0.49% +1.36% +0.52% -1.87% +0.72% Change
More quotes
Financials ($)
Sales 2017 2 037 M
EBIT 2017 419 M
Net income 2017 148 M
Finance 2017 876 M
Yield 2017 -
Sales 2018 2 547 M
EBIT 2018 807 M
Net income 2018 501 M
Finance 2018 1 700 M
Yield 2018 -
P/E ratio 2017 118,15
P/E ratio 2018 44,53
EV / Sales2017 10,3x
EV / Sales2018 7,93x
Capitalization 21 909 M
More Financials
Company
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases.It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious diseases, including... 
More about the company
Surperformance© ratings of Vertex Pharmaceuticals Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on VERTEX PHARMACEUTICALS INC
02/07 VERTEX PHARMACEUTICALS INCORPORATED : Stock Price of Vertex Pharmaceuticals Inco..
01/28 VERTEX PHARMACEUTICALS INCORPORATED : U.S. Patents Awarded to Inventors in Calif..
01/28 INGERSOLL RAND : U.S. Patents Awarded to Inventors in New Jersey (Jan. 28)
01/25 VERTEX PHARMACEUTICALS INC / MA : Results of Operations and Financial Condition,..
01/25 VERTEX PHARMACEUTICALS INCORPORATED : tops Street 4Q forecasts
01/25 VERTEX PHARMACEUTICALS INCORPORATED : Reports Full-Year and Fourth-Quarter 2016 ..
01/19 MERCK KGAA : Darmstadt, Germany, Licenses Four Oncology Research and Development..
01/19 MERCK KGAA : Darmstadt, Germany Licenses Four Oncology Research and Development ..
01/14 VERTEX PHARMACEUTICALS INCORPORATED : Merck expands oncology portfolio with four..
01/12 VERTEX PHARMACEUTICALS INCORPORATED : Patent Issued for Methods of Regioselectiv..
More news
Sector news : Bio Therapeutic Drugs
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
02/13 TEVA PHARMACEUTICAL INDUSTRIES : seeks CEO with pharma background to lead recove..
02/09DJAppeals Court Allows Sanofi, Regeneron to Continue Selling Cholesterol Drug
02/08 Weak pound buoys GSK but drugmaker warns on 2017 generic threat
More sector news : Bio Therapeutic Drugs
Latest Tweets
02/18$CELG $BIIB $VRTX $BMRN $IBB $XBI Biotech 2017 | 4 Ideas for A Stockpicker’s..
12
02/18GSA Capital Partners LLP Raises Position in Vertex Pharmaceuticals Incorporat.. 
02/17$TSRO sees a $5B market opportunity for its cancer drug
4
02/14$VRTX pushing higher
1
02/14$VRTX wound up tight over 200sma daily atm
1
More tweets
Qtime:93
News from SeekingAlpha
02/09 Buying Growth Is A Tricky Choice For Gilead
02/09 Darzalex And Keytruda Win 2016's Sell-Side Popularity Contest
02/02 Dosing underway in Galapagos' mid-study study of CF candidate GLPG2222
02/01 Will FDA And Tax Reform Occur And Help Biotech Stocks?
01/26 Concert Pharmaceuticals Set For A Transformational 2017
Advertisement
Chart VERTEX PHARMACEUTICALS INC
Duration : Period :
Vertex Pharmaceuticals Inc Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Full-screen chart
Technical analysis trends VERTEX PHARMACEUT...
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 99,0 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Ian F. Smith EVP, Chief Operating & Financial Officer
Jeffrey A. Chodakewitz Chief Medical Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Joshua S. Boger Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS..19.90%21 909
AMGEN, INC.18.52%127 620
CELGENE CORPORATION4.67%94 258
GILEAD SCIENCES, INC.-2.46%92 024
REGENERON PHARMACEUTIC..1.11%39 375
ACTELION LTD21.09%28 677
More Results